<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26933813</article-id><article-id pub-id-type="pmc">4914257</article-id><article-id pub-id-type="publisher-id">7727</article-id><article-id pub-id-type="doi">10.18632/oncotarget.7727</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper: Gerotarget (Focus on Aging)</subject></subj-group></article-categories><title-group><article-title>Rationale and design of the allogeneiC human mesenchymal stem cells (hMSC) in patients with aging fRAilTy via intravenoUS delivery (CRATUS) study: A phase I/II, randomized, blinded and placebo controlled trial to evaluate the safety and potential efficacy of allogeneic human mesenchymal stem cell infusion in patients with aging frailty</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Golpanian</surname><given-names>Samuel</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>DiFede</surname><given-names>Darcy L.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pujol</surname><given-names>Marietsy V.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lowery</surname><given-names>Maureen H.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Levis-Dusseau</surname><given-names>Silvina</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goldstein</surname><given-names>Bradley J.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schulman</surname><given-names>Ivonne H.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Longsomboon</surname><given-names>Bangon</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wolf</surname><given-names>Ariel</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Aisha</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Heldman</surname><given-names>Alan W.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goldschmidt-Clermont</surname><given-names>Pascal J.</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hare</surname><given-names>Joshua M.</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA</aff><aff id="A2"><sup>2</sup> Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA</aff><aff id="A3"><sup>3</sup> Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA</aff><aff id="A4"><sup>4</sup> Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, USA</aff><aff id="A5"><sup>5</sup> Division of Endocrinology, University of Miami Miller School of Medicine, Miami, FL, USA</aff><aff id="A6"><sup>6</sup> Division of Nephrology, University of Miami Miller School of Medicine, Miami, FL, USA</aff><aff id="A7"><sup>7</sup> Department of Otolaringology, University of Miami Miller School of Medicine, Miami, FL, USA</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Joshua M. Hare,</italic><email>jhare@med.miami.edu</email></corresp></author-notes><pub-date pub-type="collection"><day>15</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2016</year></pub-date><volume>7</volume><issue>11</issue><fpage>11899</fpage><lpage>11912</lpage><history><date date-type="received"><day>20</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Golpanian et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Frailty is a syndrome associated with reduced physiological reserves that increases an individual's vulnerability for developing increased morbidity and/or mortality. While most clinical trials have focused on exercise, nutrition, pharmacologic agents, or a multifactorial approach for the prevention and attenuation of frailty, none have studied the use of cell-based therapies. We hypothesize that the application of allogeneic human mesenchymal stem cells (allo-hMSCs) as a therapeutic agent for individuals with frailty is safe and efficacious. The CRATUS trial comprises an initial non-blinded phase I study, followed by a blinded, randomized phase I/II study (with an optional follow-up phase) that will address the safety and pre-specified beneficial effects in patients with the aging frailty syndrome. In the initial phase I protocol, allo-hMSCs will be administered in escalating doses via peripheral intravenous infusion (n=15) to patients allocated to three treatment groups: Group 1 (n=5, 20 million allo-hMSCs), Group 2 (n=5, 100 million allo-hMSCs), and Group 3 (n=5, 200 million allo-hMSCs). Subsequently, in the randomized phase, allo-hMSCs or matched placebo will be administered to patients (n=30) randomly allocated in a 1:1:1 ratio to one of two doses of MSCs versus placebo: Group A (n=10, 100 million allo-hMSCs), Group B (n=10, 200 million allo-hMSCs), and Group C (n=10, placebo). Primary and secondary objectives are, respectively, to demonstrate the safety and efficacy of allo-hMSCs administered in frail older individuals. This study will determine the safety of intravenous infusion of stem cells and compare phenotypic outcomes in patients with aging frailty.</p></abstract><kwd-group><kwd>aging</kwd><kwd>frailty</kwd><kwd>mesenchymal stem cells</kwd><kwd>allogeneic</kwd><kwd>Gerotarget</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Frailty is defined as a medical condition, which can be caused by multiple stressors, characterized by decreased strength, endurance, and physiologic function that increases the risk of developing dependency and/or mortality [<xref rid="R1" ref-type="bibr">1</xref>]. The etiology of these increased risks can be, at least partially, attributed to the critically low &#x0201c;reserve capacity&#x0201d; of various organ systems, at which point a minor disturbance can create a cascade of medically catastrophic events [<xref rid="R2" ref-type="bibr">2</xref>]. The syndrome has an estimated overall prevalence of 10%, with a higher prevalence found in women and in patients with chronic disease [<xref rid="R3" ref-type="bibr">3</xref>].</p><p>Frail individuals are major consumers of medical resources, hospitalizations, and nursing homes. Importantly, it is believed that early intervention for this medical syndrome can improve patient quality of life as well as help lower costs of care [<xref rid="R4" ref-type="bibr">4</xref>]. Currently, there are no specific FDA-approved treatments and thus no established pharmacologic gold standard-of-care for frail patients. Certain features of the frailty syndrome have established a potential role for adult human mesenchymal stem cells (hMSCs) to improve its symptoms. Specifically, allo-hMSCs have been shown to improve cardiac function in patients with acute myocardial infarction [<xref rid="R5" ref-type="bibr">5</xref>] (AMI) and chronic ischemic cardiomyopathy [<xref rid="R6" ref-type="bibr">6</xref>] in exert profound and sustained anti-inflammatory effects [<xref rid="R7" ref-type="bibr">7</xref>].</p><p>The purpose of the CRATUS study is to address several key questions related to allo-hMSC therapy and its novel use in patients with frailty. This study will test the safety of intravenous (IV) infusion of allo-hMSCs in frail subjects and will also assess the efficacy of treatment in this population at risk for morbidity and mortality.</p></sec><sec id="s2"><title>DISCUSSION</title><p>With a growing aging population the number of individuals in the oldest age brackets will increase at the highest rate [<xref rid="R8" ref-type="bibr">8</xref>]. Frailty syndrome is a common medical entity in the geriatric population and its prevalence increases with age [<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>]. The absence of a consensus on its exact diagn ostic criteria exists together with the concomitant establishment of different models used to describe the syndrome can at least partially explain why the prevalence of frailty has varied so greatly among studies [<xref rid="R11" ref-type="bibr">11</xref>]&#x02014;between 4% and 59.1% with a weighted average of 9.9% [<xref rid="R3" ref-type="bibr">3</xref>]. It has been associated with an increased risk of worse clinical outcome [<xref rid="R12" ref-type="bibr">12</xref>] and is known to be a major independent risk factor for falls, disability, hospitalizations, and mortality in older individuals [<xref rid="R13" ref-type="bibr">13</xref>]. Importantly, the clinical syndrome is dynamic, and exists as a broad spectrum. As such, the phenotype is based on an accumulation of various disabilities and comorbidities and has allowed patients to be categorized as fit, pre-frail, or frail, with varying degrees within each classification-type [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>]. Thus, the frailty syndrome is multifaceted in nature and derives from a complex set of interactions between physical, psychological, and social aspects of an individual.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Peripheral intravenous administration of allogeneic MSCs via systemic circulation</title></caption><graphic xlink:href="oncotarget-07-11899-g001"/></fig><p>The process of aging has been characterized as having multiple hallmarks including, but not limited to, stem cell exhaustion, mitochondrial dysfunction, and altered intercellular communication related to inflammation [<xref rid="R16" ref-type="bibr">16</xref>]. A pathologic or accelerated process of aging can lead to the frailty syndrome [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. The decline in physiological systems is related to the abnormal and disrupted communication between them and has been biologically linked to the chronic elevation of various inflammatory cytokines, which considered one of the most notable hallmarks of frailty [<xref rid="R19" ref-type="bibr">19</xref>]. Indeed, several studies have indicated that elevated levels of interleukin-6 (IL-6), C-reactive protein (CRP), and white blood cell (WBC) count play a key role in systemic inflammation (Figure <xref ref-type="fig" rid="F2">2</xref>) and consequent organ dysregulation in individuals with aging frailty [<xref rid="R20" ref-type="bibr">20</xref>-<xref rid="R22" ref-type="bibr">22</xref>]. Although the cellular basis of these changes remains incompletely understood, there is an emerging field of science suggesting mitochondrial dysfunction, cellular senescence, telomere shortening, and increased levels of free radicals to be key elements in the molecular pathophysiology [<xref rid="R23" ref-type="bibr">23</xref>]. Moreover, endogenous stem cell production decreases with age and likely contributes to diminished organ system repair and homeostasis in frailty</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Systemic inflammation</title><p><bold>A.</bold> Areas in red color depict widespread inflammation. <bold>B.</bold> MSCs migrate to regions of injury and exert their anti-inflammatory properties (green color).</p></caption><graphic xlink:href="oncotarget-07-11899-g002"/></fig><p>Several scoring systems and indexes have been used as clinical assessment tools for frailty [<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>]. The Canadian Study of Health and Aging Clinical Frailty Scale [<xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>] (CSHA-CFS) is a clinical scale that measures the severity of an individual's frailty based on the physician's judgment rather than the presence or absence of specific items (i.e., grip test), which allows for a broader patient evaluation. Various investigators in numerous studies on frailty have corroborated its use in the clinical setting [<xref rid="R28" ref-type="bibr">28</xref>-<xref rid="R31" ref-type="bibr">31</xref>]. Diagnostic models and instruments have helped investigators formulate more effective treatment modalities for frail individuals. The remediation of frailty syndrome is crucial for both patient quality of life and the public health burden [<xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R33" ref-type="bibr">33</xref>]. Frailty has been described to have a continuum of &#x0201c;states&#x0201d; that frail individuals frequently transition between [<xref rid="R34" ref-type="bibr">34</xref>]. These changes can be bidirectional, although the switch from less severe frailty to more severe frailty is more common than the reverse. This can allow for early intervention to help delay and/or attenuate the functional decline in persons with frailty [<xref rid="R35" ref-type="bibr">35</xref>].</p><p>A significant amount of literature [<xref rid="R36" ref-type="bibr">36</xref>-<xref rid="R40" ref-type="bibr">40</xref>] addresses the importance and validity of interventions to help prevent and attenuate frailty. Yet clinical trials have mainly focused on implementing exercise regimens [<xref rid="R41" ref-type="bibr">41</xref>], nutritional supplementation [<xref rid="R42" ref-type="bibr">42</xref>], a combination of exercise and nutrition [<xref rid="R43" ref-type="bibr">43</xref>], pharmacologic agents [<xref rid="R44" ref-type="bibr">44</xref>], or multidisciplinary interventions [<xref rid="R45" ref-type="bibr">45</xref>]. To date, there has been no published data on the safety and efficacy of cell-based therapy for frailty syndrome. In this regard, mesenchymal stem cell (MSC) therapy could potentially ameliorate signs and symptoms of frailty. MSCs have been particularly appealing to investigators due to its easy isolation from multiple tissues and ability to differentiate into many cell lines [<xref rid="R46" ref-type="bibr">46</xref>, <xref rid="R47" ref-type="bibr">47</xref>]. In addition, their migratory ability and immunopriveleged state has generated much interest in its systemic application, via peripheral intravenous infusion, for a multitude of disease processes [<xref rid="R48" ref-type="bibr">48</xref>-<xref rid="R51" ref-type="bibr">51</xref>] (Figure <xref ref-type="fig" rid="F3">3</xref>). The use of allo-hMSCs, derived from young healthy donors, avoids the aging-related aberrant microenvironments of MSCs, and thus the &#x0201c;inflamm-aged&#x0201d; MSCs obtained from older individuals [<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R52" ref-type="bibr">52</xref>]. Allogeneic hMSCs not only help replenish exhausted and/or senescent native stem cells but also have demonstrated systemic anti-inflammatory properties [<xref rid="R7" ref-type="bibr">7</xref>] (Figure <xref ref-type="fig" rid="F2">2</xref>). Importantly, the safety of MSCs derived from healthy adult donors has been validated in numerous clinical investigations [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R53" ref-type="bibr">53</xref>, <xref rid="R54" ref-type="bibr">54</xref>]. Therefore, this therapeutic agent holds great promise as a potential, novel treatment for individuals with frailty. Furthermore, a valuable aspect of this work will be to examine and understand the mechanistic basis underlying the beneficial effects. Patients will undergo additional tests such as biomarker assessments, immune monitoring, and endothelial function assessment [<xref rid="R55" ref-type="bibr">55</xref>] to help elucidate mechanism of action.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>MSC effects on organ systems</title><p>MSCs target various tissues throughout the body to help enhance cardiac reserve (heart), improve endothelial function (blood vessels), reduce inflammation (diffusely and in joints), and increase bone density (bone) and muscle tone (skeletal muscle) through pro-regenerative effects (i.e., paracrine signaling, mitochondrial transfer, exosomes).</p></caption><graphic xlink:href="oncotarget-07-11899-g003"/></fig></sec><sec sec-type="methods" id="s3"><title>MATERIALS AND METHODS</title><sec id="s3_1"><title>Study objectives</title><p>The primary objective of the study is to demonstrate the safety of allo-hMSCs in patients with frailty, and the secondary objective is to explore treatment efficacy including decrease in frailty, frequency of acute exacerbations, change in symptom-related quality of life, improved cardiovascular status, decrease in inflammatory biomarkers, endothelial function and 1-year survival. The optional follow-up phase will have the same primary and secondary objectives.</p></sec><sec id="s3_2"><title>Study design</title><p>The initial phase of this study will be non-blinded phase I study that will be performed to test the safety of the dose and volume escalation of cells administered via peripheral intravenous infusion (Figure <xref ref-type="fig" rid="F1">1</xref>). The second portion of the study will be a phase I/II blinded, randomized, placebo-controlled study that will be conducted after a full review of the safety data from the phase I by an independent Data and Safety Monitoring Board (DSMB). Approximately 15 subjects will be enrolled in the pilot phase and 30 subjects will be enrolled in the randomized phase for a total of 45 subjects.</p><p>All patients will provide written informed consent on the University of Miami Institutional Review Board-approved protocol. Upon successfully fulfilling inclusion-exclusion criteria (Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref>) patients will receive either 20 million, 100 million, or 200 million allo-hMSCs in the lead-in phase I, and patients in the randomized phase will be randomized 1:1:1 to an active arm (100 million allo-hMSCs or 200 million allo-hMSCs) or placebo. The optional follow-up phase, in which all 15 patients of the initial pilot phase are eligible to participate, is designed to test the safety and tolerability of a second infusion of allo-hMSCs 12 to 18 months following the first infusion (100 million allo-hMSCs).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Major inclusion criteria</title></caption><table frame="box" rules="all"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Must provide written informed consent</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Subjects age &#x02265;60 and &#x02264;95 years at the time of signing the informed consent form</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Must show signs of frailty apart from a concomitant condition as assessed by the investigator with a frailty score of 4 to 7 using the Canadian Clinical Frailty Scale.</td></tr></tbody></table><table-wrap-foot><fn id="tfn_001"><label>*</label><p>Patients in the optional follow-up phase must have previously participated in the pilot phase of the trial and female subjects must have an FSH &#x02265; 25.8 IU/L</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Major exclusion criteria</title></caption><table frame="box" rules="all"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Must not score &#x02264;24 on the Mini Mental State Examination (MMSE)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Inability to perform any of the assessments required for endpoint analyses (report safety or tolerability concerns, perform pulmonary function tests (PFTs), undergo blood draw, read and respond to questionnaires</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Active listing (or expected future listing) for transplant of any organ</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Clinically important abnormal screening laboratory values, including but not limited to: hemoglobin &#x0003c;8 g/dL, white blood cell count &#x0003c;3000/mm3, platelets &#x0003c;80,000/mm3, INR &#x0003e;1.5 not due to a reversible cause (i.e. Coumadin), aspartate transaminase, alanine transaminase, or alkaline phosphatase &#x0003e;3 times the upper limit of normal, total bilirubin &#x0003e;1.5 mg/dL</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study including but not limited to: HIV, advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, cardiac revascularization with the last 6 months, or severe obstructive ventilator defect</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Have known allergies to penicillin or streptomycin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Be an organ transplant recipient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease-free for at least 5 years) except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ, or cervical carcinoma if recurrence occurs</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Have a non-pulmonary condition that limits lifespan to &#x0003c;1 year</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Have a history of drug or alcohol abuse within the past 24 months</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Be serum-positive for HIV, hepatitis BsAg or viremic hepatitis C</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Be currently participating (or participiated within the previous 30 days) in an investigational therapeutic or device trial</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Female subjects must have an FSH &#x0003c;25.8 IU/L</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Have a hypersensitivity to dimethyl sulfoxide (DMSO)</td></tr></tbody></table></table-wrap><p>In the randomized phase of the trial, subjects who received placebo will have the option to receive allo-hMSCs, if all endpoints are met, at which time the subjects will be administered the study drug and follow the study schedule from Day 1 to Month 12 after receiving the infusion of allo-hMSCs.</p></sec><sec id="s3_3"><title>Outcome measures for safety</title><p>The primary outcome measure for safety will include the incidence (at 1 month post-infusion) of any treatment emergent serious adverse events (TE-SAEs), defined as the composite of death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea, and clinically significant laboratory test abnormalities. Continued safety and tolerability with review of clinical laboratory tests and adverse events (AEs) will be monitored at each visit for the pilot and randomized studies, through 12 months. For the optional follow-up phase, the incidence of adverse events will be described at 30-days, 6- and 12-months post second infusion.</p></sec><sec id="s3_4"><title>Outcome measures for efficacy</title><p>The secondary efficacy endpoints will be evaluated in this trial at baseline, 3-month, and 6-month follow-up visits. They will include the difference in rate of decline of frailty defined as: reduced activity (assessed via CHAMPS questionnaire), slowing of mobility (assessed via a 4 meter gait speed test and 6-minute walk test), weight loss, diminished handgrip strength (assessed via dynamometer and short physical performance battery (SPPB) assessment), and exhaustion (assessed via the multidimensional fatigue inventory (MFI) questionnaire); difference in subject quality of life assessment(s); death from any cause; exercise change in ejection fraction; and the following panel of inflammatory markers: C-reactive protein (CRP), Interleukin-6 (IL-6), D-dimer, fibrinogen, complete blood count (CBC) with differential, DNA, and tumor necrosis factor (TNF)-&#x003b1;. In the optional follow-up phase of the study, secondary efficacy endpoints will only be evaluated during baseline and 6-month follow-up visits. A summary of study procedure time and events can be seen in Table <xref ref-type="table" rid="T3">3</xref>. Patient status and freedom from adverse and serious adverse events will be ascertained at 12 months by telephone contact.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Time and events</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Study Procedure</th><th align="left" valign="middle" rowspan="1" colspan="1">Screening<break/>Day -56<break/>(&#x000b1;28 days)</th><th align="left" valign="middle" rowspan="1" colspan="1">Baseline<break/>(&#x02212;4 weeks)</th><th align="left" valign="middle" rowspan="1" colspan="1">Day 1</th><th align="left" valign="middle" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="tfn_010">*</xref>Week 2<break/>(Day 14) (&#x000b1;2 days)</th><th align="left" valign="middle" rowspan="1" colspan="1">Month 1<break/>(Day 30)<break/>(&#x000b1;2 weeks)</th><th align="left" valign="middle" rowspan="1" colspan="1">Month 3 (Day 90)<break/>(&#x000b1;2 weeks)</th><th align="left" valign="middle" rowspan="1" colspan="1">Month 6 (Day 180)<break/>(&#x000b1;2 weeks)</th><th align="left" valign="middle" rowspan="1" colspan="1">Month 12<break/>(Day 365)<break/>(&#x000b1;2 weeks)<break/>**Phone Call Follow-up</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Informed Consent</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Full Medical History</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Physical Exam</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">12-lead (ECG)</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Concomitant Medications</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mini Mental State Examination (MMSE)</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Randomization</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Infusion Treatment (IP)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dobutamine Stress Echo Test (DSE)</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bone Density Scan (DEXA)<xref ref-type="table-fn" rid="tfn_009"><sup>8</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FEV-1</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">6-Minute Walk Test</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4-Meter Gait Speed Test<xref ref-type="table-fn" rid="tfn_008"><sup>7</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SPPB Assessment</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dynamometer (handgrip)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smell Identification Test (UPSIT)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IIEF, SQOL-F Questionnaires</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QOL Questionnaires (ICECAP, EQ-5D, SF-36, CHAMPS, MFI)</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Urinalysis</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hemat., Chem., CBC, LFTs, INR, and other labs<xref ref-type="table-fn" rid="tfn_002"><sup>1</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HIV 1, HIV 2, Hep. B &#x00026; C, and CMV</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Serum or Urine Pregnancy Test<xref ref-type="table-fn" rid="tfn_003"><sup>2</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Donor Screening Tests</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Review Adverse Events</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Immune Monitoring<xref ref-type="table-fn" rid="tfn_005"><sup>4</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Biomarker Assessment<xref ref-type="table-fn" rid="tfn_004"><sup>3</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Optional: Brachial Ultrasound<xref ref-type="table-fn" rid="tfn_006"><sup>5</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Optional: Endothelial blood samples<xref ref-type="table-fn" rid="tfn_007"><sup>6</sup></xref></td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1">x</td><td align="left" valign="middle" rowspan="1" colspan="1"/><td align="left" valign="middle" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Subjects have up to 4 weeks to complete all baseline visit procedures before Day 1</p><fn id="tfn_002"><label>1</label><p>The minimal laboratory requirements for hematological, liver function and renal function include: Hematology tests- white blood cell count, platelet count, hemoglobin and hematocrit; Liver function tests- albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, prothrombin time, activated partial thromboplastin time, and bilirubin; Renal function tests- creatinine, creatinine clearance, blood urea nitrogen, glomerular filtration rate, sodium, potassium, chloride, carbon dioxide, and glucose; serum uric acid, pro-BNP, C-reactive protein, IL-6, fibrinogen, and D-dimer</p></fn><fn id="tfn_003"><label>2</label><p>A serum or urine pregnancy test will be completed within 36 hours prior to injection for females of childbearing potential</p></fn><fn id="tfn_004"><label>3</label><p>The following biomarkers will be analyzed: Cell-surface markers- CXCR4, C-kit, and Connexin 43; Transcriptomic/Proteome-RNA, miRNA, protein samples and telomerase, and Akt; Growth factors- Sdf-1, Notch; Function assays- cell growth rate, VEGF, and CFU assay</p></fn><fn id="tfn_005"><label>4</label><p>Immune monitoring for graft rejection. The following markers will be used for analysis to assess for activated T-cells based upon a CD3+CD25+ or CD3+CD69+ phenotype: CD3, CD25, CD69</p></fn><fn id="tfn_006"><label>5</label><p>Optional: An addition 5 lavender top tubes (EDTA) will be drawn</p></fn><fn id="tfn_007"><label>6</label><p>Optional brachial ultrasound to assess endothelial function</p></fn><fn id="tfn_008"><label>7</label><p>4-meter gait speed test will be performed twice per visit and the average of the exams will be taken</p></fn><fn id="tfn_009"><label>8</label><p>DEXA scan will be performed twice at each visit. The first scan will be of the hip and spine for bone density and the second will be to assess the total body composition</p></fn><fn id="tfn_010"><label>*</label><p>Patients in the optional follow-up phase will not be assessed at Week 2</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3_5"><title>Blinding/randomization</title><p>The second phase of the study will be a phase I/II double-blinded, randomized, placebo-controlled trial. Patients will be randomized to treatment strategy (100 million allo-hMSCs, 200 million allo-hMSCs, or placebo) in a 1:1:1 ratio via electronic randomization using the Advantage EDC system and communicated to cellular laboratory personnel who have no contact with the investigators or subjects. At the time of administration, opaque tubing will be used for study product infusion in order to maintain double-blinding.</p></sec><sec id="s3_6"><title>Donor eligibility/cell harvesting</title><p>Male or female donors between the ages of 20 to 45 will be screened at potential bone marrow (BM) donors. A maximum of 15 subjects will be evaluated by history and physical examination. A summary of the screening history and physical as well as eligibility criteria for normal donors is shown on Tables <xref ref-type="table" rid="T4">4</xref> and <xref ref-type="table" rid="T5">5</xref>. Informed consent will be obtained from all potential donors. After discharge from the hospital, bone marrow donors will be contacted by the study team with a follow-up telephone call to determine the well-being and health status of the donor.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Normal donor history and physical examination</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">History</th><th align="left" valign="middle" rowspan="1" colspan="1">Physical</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">History of malignancy<break/>Bleeding abnormalities<break/>Prior deep venous thrombosis<break/>Known cardiac or pulmonary conditions<break/>Prior blood transfusions<break/>Vaccinations<break/>Questions to identify persons at risk of infectious disease transmission<break/>Questions to identify persons at risk of transmitting hematological or immunological disease<break/>A physician will administer the National Marrow Donor Program (NMDP) Questionnaire (a donor health history screening questionnaire)</td><td align="left" valign="middle" rowspan="1" colspan="1">Complete physical examination<break/>Infectious disease testing including:<break/>Hepatitis B surface antigen (HBsAg)<break/> Anti-Hepatitis B core antibody (HBcAb)<break/> Anti-Hepatitis C virus antibody (HCVAb)<break/> Anti-Human Immunodeficiency Virus (HIV) antibody (HIV 1/2)<break/>Cytomegalovirus antibody (CMV)<break/>HCV/HIV Nucleic Acid test<break/> West Nile Virus Nucleic Acid test<break/>Rapid Plasma Reagin (RPR)<break/>Human T-lymphotropic Virus I/II (HTLV I/II)<break/>T. cruzi ELISA test (Chagas disease)<break/> Complete blood count (CBC) with differential<break/>Complete metabolic panel (CMP), magnesium (Mg<sup>2+</sup>), Calcium (Ca<sup>2+</sup>), and uric acid</td></tr></tbody></table></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Normal donor eligibility criteria</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Male and female gender</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">No history of malignancy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No active coagulopathy and/or hypercoagulable state</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No history of cardiopulmonary conditions</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Negative tests for Hepatitis B, Hepatitis C, RPR, Chagas disease, HIV 1/2, HTLV I/II, and NAT for HCV, HIV, and WNV</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hemoglobin &#x02265;13.0 g/dL</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Platelet count 140,000 to 440,000/ul</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WBC 3.0 to 11.0 K/ul</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No anomalies on the CBC and differential suggestive of a hematopoietic disorder</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Creatinine &#x02264;1.5 mg/dL</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALT &#x02264;112 IU/L</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bilirubin &#x0003c;1.5 mg/dL</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No diabetes</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Systolic blood pressure (SBP) &#x02264;170 mmHg</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diastolic blood pressure (DBP) &#x02264;90 mmHg</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No history of autoimmune disorders</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Negative serum or urine pregnancy test for female donors</td></tr></tbody></table></table-wrap><p>A total of 120 mL of BM will be obtained from each normal volunteer. BM will be aspirated from the posterior iliac crest into heparinized syringes. The mononuclear cell fraction will be isolated using a density gradient with Lymphocyte Separation Media (specific gravity 1.077). The low-density cells will be collected and washed with Plasma-LyteA containing 1% HAS. The washed cells will be sampled and viable cell numbers determined. The BM mononuclear cells will be seeded into 225 cm<sup>2</sup> tissue culture flasks in alpha MEM containing 20% FBS. After 14 days of culture, passage zero (P0) cells will be harvested by trypsin treatment and expanded into 60 flasks. These flasks are incubated for a further 7 to 10 days and then the MSCs are harvested by trypsin treatment (P1 cells).</p><p>For the optional follow-up phase, allo-hMSCs will be derived from approximately 2 &#x02013; 3 normal donors meeting criteria for allogeneic unrelated human bone marrow source manufactured by the University of Miami.</p></sec><sec id="s3_7"><title>Biomarker assessment</title><p>A separate 7 mL blood sample for gene expression profiling of white blood cell RNA will be obtained at the donation visit. All samples will be identified so that they can be linked to individual patient and may be stored indefinitely. Individual results will not be returned to the patient or the study physician; only aggregate data from the entire study will be disclosed.</p></sec><sec id="s3_8"><title>Immune monitoring for graft rejection</title><p>We will obtain peripheral blood samples from all patients to evaluate the presence of activated T-cells. Two heparinized tubes will be collected at different time points during the study (Day 1 prior to infusion of allo-hMSC and Month 6). Peripheral blood mononuclear cells (PMNCs) will be isolated from heparinized blood by Ficoll sedimentation and will be viably cryopreserved for planned assessments of early and late T-cell activation and B-cell subsets. Additionally, in female patients who receive allo-hMSCs, the stored baseline serum will be analyzed to evaluate the antibody responses to HLA and H-Y antigens.</p></sec><sec id="s3_9"><title>Infusion</title><p>Prior to the start of the infusion the following procedures and assessments will be conducted on the study subject:
<list list-type="order"><list-item><p>Vital signs: Blood pressure, heart rate, respiratory rate, and temperature will be measured within 15 minutes prior to the initiation of infusion.</p></list-item><list-item><p>Oxygen saturation will be continuously monitored by pulse oximetry for at least 30 minutes prior to initiation of infusion.</p></list-item><list-item><p>Confirm that peripheral intravenous (IV) access is established and that the IV catheter is no smaller than 20 gauge.</p></list-item><list-item><p>Study personnel need to verify and document that the following pre-medications have been administered 30 minutes prior to infusion per protocol: Hydrocortisone 25-50 mg IV and Diphenhydramine 25-50 mg IV.</p></list-item><list-item><p>Required IV infusion materials as follows: 0.9% normal saline IV infusion bag, IV pump tubing, IV extension tubing, volumetric infusion pump, and gloves.</p></list-item><list-item><p>Remove 0.9% normal saline infusion bag and connect IV tubing to the volumetric infusion pump.</p></list-item><list-item><p>Cover the IV tubing with the blinding material provided with the infusion bag by the drug preparation technician.</p></list-item></list></p><p>During the infusion of the following procedures and assessments will be conducted on the study subject:
<list list-type="order"><list-item><p>Monitor the subject continuously with pulse oximetry.</p></list-item><list-item><p>Hang the blinded infusion bag (investigational product should not be &#x0201c;piggybacked&#x0201d; through another line).</p></list-item><list-item><p>Intravenously administer the product at a rate of 2 mL/min with the study personnel present throughout the infusion process and the investigator available at the site in case an emergency arises.</p></list-item><list-item><p>Record the start time of the infusion bag.</p></list-item><list-item><p>Gently squeeze the infusion bag several times every 15 minutes to assure uniform dispersion of contents.</p></list-item><list-item><p>Measurement of vital signs and oxygen saturation every 15 minutes until the end of the infusion.</p></list-item><list-item><p>Record the total volume from the investigational product bag.</p></list-item></list></p><p>At the end of the infusion, the line will be closed and flushed with 25 mL of 0.9% normal saline into the luer lock connecter on the bottom of the bag, and then reopened to allow the infusion of the saline at a rate of 2 mL/min until completion. Vital signs will be monitored at 15 minutes, 30 minutes, 1 hour, and 2 hours post-infusion. The subject will be monitored for a minimum of 2 hours post-infusion with continuous pulse oximetry. If the oxygen saturation decreases to &#x0003c;90% over a continual period of 3 &#x02013; 5 minutes, then supplemental oxygen may be added or increased during the 2-hr post-infusion observation period. If at the end of the 2-hour observation period a subject's oxygen saturation remains below 90%, then the subject will be provided additional oxygen to maintain a saturation of &#x0003e;90% at room air up to 4 hours post-infusion. After the minimum 2-hour observation period, the subject will be continuously monitored and discharged the following day if no complaints (i.e. shortness of breath or other objective signs of cardiorespiratory compromised) are experienced. Subjects not meeting criteria for discharge will be assessed by the investigator during the observation period to further determine hospitalization.</p><p>Intravenous infusion will be discontinued if the oxygen saturation does not return to &#x0003e;93% within 3 minutes of initiation supplemental oxygen or if the patient requires greater than 2 L/min supplemental oxygen to achieve the required saturation of &#x0003e;93%. Any subject whose infusion is stopped due to cardiorespiratory distress will receive no further infusions but will continue with all scheduled follow-up if such follow-up is considered safe in the opinion of the investigator.</p></sec><sec id="s3_10"><title>Dosing</title><p>During the pilot phase of the study, a total of 15 subjects will receive a single infusion of allo-hMSCs (Figure <xref ref-type="fig" rid="F1">1</xref>):
<list list-type="simple"><list-item><p>Group 1 (5 subjects) will be treated with a single administration of 2 &#x000d7; 10<sup>7</sup> (20 million) allo-hMSCs delivered via peripheral intravenous infusion.</p></list-item><list-item><p>Group 2 (5 subjects) will be treated with a single administration of 1 &#x000d7; 10<sup>8</sup> (100 million) allo-hMSCs delivered via peripheral intravenous infusion.</p></list-item><list-item><p>Group 3 (5 subjects) will be treated with a single administration of 2 &#x000d7; 10<sup>8</sup> (200 million) allo-hMSCs delivered via peripheral intravenous infusion.</p></list-item></list></p><p>In the randomized phase, a total of 30 subjects will be randomized in a 1:1:1 ratio to one of two treatment strategies or placebo following completion of the pilot phase:
<list list-type="simple"><list-item><p>Group A will consist of 10 subjects that will receive 1 &#x000d7; 10<sup>8</sup> (100 million) allo-hMSCs delivered via peripheral intravenous infusion.</p></list-item><list-item><p>Group B will consist of 10 subjects that will receive 2 &#x000d7; 10<sup>8</sup> (200 million) allo-hMSCs delivered via pheripheral intravenous infusion.</p></list-item><list-item><p>Group C will consist of 10 subjects that will receive placebo via peripheral intravenous infusion.</p></list-item><list-item><p>After subjects complete their Month 12 follow-up phone call visit in the pilot phase, all 15 subjects will then have the option of receiving a second single infusion of allo-hMSCs. Subjects will be treated with a single administration of 1 &#x000d7; 10<sup>8</sup> (100 million) allo-hMSCs delivered via peripheral intravenous infusion.</p></list-item></list></p></sec><sec id="s3_11"><title>Statistical analysis</title><p>All statistical tests will be performed at an &#x003b1; =0.05 level of significance, using two-sided tests. Because this is a phase I/II study with exploratory efficacy outcomes, no adjustments will be made for multiple analyses, as previously discussed [<xref rid="R56" ref-type="bibr">56</xref>]. Continuous variables will be presented by descriptive statistics. Categorical variables will be presented by counts. Two-sided 95% confidence intervals will be calculated and presented where appropriate.</p><p>Analysis of AEs will include tabulation by frequency, severity, organ system affected, and relationship to study exposure. Lung function data will be summarized descriptively. Patient reported outcome data will be summarized according to the guidelines of each questionnaire. Comparison of AE and SAE rates will be evaluated between cell groups and placebo using Fisher Exact Test.</p></sec><sec id="s3_12"><title>Safety and monitoring</title><p>Interim analyses will be conducted at times coincident with regularly scheduled meetings of the DSMB at approximately six-month intervals. The DSMB Chair will be notified each time and SAE occurs. After all patients in in the pilot phase have been followed for 30 days, an independent DSMB will review all available data to make an independent recommendation to either keep the specified randomized dose 1:1:1 or to recommend a dose modification for the randomized placebo study.</p></sec></sec><sec id="s4"><title>CONCLUSION</title><p>In conclusion, the CRATUS study is designed to demonstrate the safety of allo-hMSCs administered in patients with frailty. The results of this study will also provide novel information about the efficacy and mechanism of action of cell therapy in this important elderly population with frailty syndrome.</p></sec></body><back><ack><p>All authors have provided the corresponding author with written permission to be names in the manuscript. They all have reviewed and approved the final version of the manuscript. The authors are solely responsible for the design and conduct of the study, interpretation of the data, and the contents of the article.</p></ack><fn-group><fn fn-type="conflict"><p><bold>CONFLICTS OF INTEREST</bold></p><p>Drs. Hare reports equity interest in Longeveron and Vestion.</p></fn><fn fn-type="supported-by"><p><bold>FUNDING</bold></p><p>This study was provided support by The Starr Foundation and The Soffer Family Foundation. This trial is listed on <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link> (NCT02065245).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>van Kan</surname><given-names>GA</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><name><surname>Bauer</surname><given-names>JM</given-names></name><name><surname>Bernabei</surname><given-names>R</given-names></name><name><surname>Cesari</surname><given-names>M</given-names></name><name><surname>Chumlea</surname><given-names>WC</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Fried</surname><given-names>LP</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Katz</surname><given-names>PR</given-names></name><name><surname>Malmstrom</surname><given-names>TK</given-names></name><name><surname>McCarter</surname><given-names>RJ</given-names></name><name><surname>Gutierrez Robledo</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Frailty consensus: a call to action</article-title><source>J Am Med Dir Assoc</source><year>2013</year><volume>14</volume><fpage>392</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">23764209</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Oude Voshaar</surname><given-names>RC</given-names></name><name><surname>Benraad</surname><given-names>C</given-names></name><name><surname>Olde Rikkert</surname><given-names>M.G.M.</given-names></name></person-group><chapter-title>Kwetsbaarheid, complexiteit en welbevinden bij ouderen</chapter-title><person-group person-group-type="editor"><name><surname>Leentjes</surname><given-names>A. GROB</given-names></name><name><surname>Schols</surname><given-names>J.M.G.A</given-names></name><etal/></person-group><source>Handboek Multidisciplinaire Zorg</source><publisher-loc>Utrecht</publisher-loc><publisher-name>De Tijdstroom</publisher-name><year>2010</year><fpage>43</fpage><lpage>62</lpage></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collard</surname><given-names>RM</given-names></name><name><surname>Boter</surname><given-names>H</given-names></name><name><surname>Schoevers</surname><given-names>RA</given-names></name><name><surname>Oude Voshaar</surname><given-names>RC</given-names></name></person-group><article-title>Prevalence of frailty in community-dwelling older persons: a systematic review</article-title><source>J Am Geriatr Soc</source><year>2012</year><volume>60</volume><fpage>1487</fpage><lpage>1492</lpage><pub-id pub-id-type="pmid">22881367</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerreta</surname><given-names>F</given-names></name><name><surname>Eichler</surname><given-names>HG</given-names></name><name><surname>Rasi</surname><given-names>G</given-names></name></person-group><article-title>Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>1972</fpage><lpage>1974</lpage><pub-id pub-id-type="pmid">23171092</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Traverse</surname><given-names>JH</given-names></name><name><surname>Henry</surname><given-names>TD</given-names></name><name><surname>Dib</surname><given-names>N</given-names></name><name><surname>Strumpf</surname><given-names>RK</given-names></name><name><surname>Schulman</surname><given-names>SP</given-names></name><name><surname>Gerstenblith</surname><given-names>G</given-names></name><name><surname>DeMaria</surname><given-names>AN</given-names></name><name><surname>Denktas</surname><given-names>AE</given-names></name><name><surname>Gammon</surname><given-names>RS</given-names></name><name><surname>Hermiller</surname><given-names>JB</given-names><suffix>Jr</suffix></name><name><surname>Reisman</surname><given-names>MA</given-names></name><name><surname>Schaer</surname><given-names>GL</given-names></name><name><surname>Sherman</surname><given-names>W</given-names></name></person-group><article-title>A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>54</volume><fpage>2277</fpage><lpage>2286</lpage><pub-id pub-id-type="pmid">19958962</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Fishman</surname><given-names>JE</given-names></name><name><surname>Gerstenblith</surname><given-names>G</given-names></name><name><surname>DiFede Velazquez</surname><given-names>DL</given-names></name><name><surname>Zambrano</surname><given-names>JP</given-names></name><name><surname>Suncion</surname><given-names>VY</given-names></name><name><surname>Tracy</surname><given-names>M</given-names></name><name><surname>Ghersin</surname><given-names>E</given-names></name><name><surname>Johnston</surname><given-names>PV</given-names></name><name><surname>Brinker</surname><given-names>JA</given-names></name><name><surname>Breton</surname><given-names>E</given-names></name><name><surname>Davis-Sproul</surname><given-names>J</given-names></name><name><surname>Schulman</surname><given-names>IH</given-names></name><name><surname>Byrnes</surname><given-names>J</given-names></name><name><surname>Mendizabal</surname><given-names>AM</given-names></name><name><surname>Lowery</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial</article-title><source>JAMA</source><year>2012</year><volume>308</volume><fpage>2369</fpage><lpage>2379</lpage><pub-id pub-id-type="pmid">23117550</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>DJ</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Flannery</surname><given-names>R</given-names></name><name><surname>LeRoux-Williams</surname><given-names>M</given-names></name><name><surname>Tashkin</surname><given-names>DP</given-names></name></person-group><article-title>A placebo-controlled, randomized trial of mesenchymal stem cells in COPD</article-title><source>Chest</source><year>2013</year><volume>143</volume><fpage>1590</fpage><lpage>1598</lpage><pub-id pub-id-type="pmid">23172272</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>E.</given-names></name></person-group><article-title>2008-based national population projections for the United Kingdom and constituent countries</article-title><source>Popul Trends</source><year>2010</year><issue>139</issue><fpage>91</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">20379280</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>LP</given-names></name><name><surname>Tangen</surname><given-names>CM</given-names></name><name><surname>Walston</surname><given-names>J</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Hirsch</surname><given-names>C</given-names></name><name><surname>Gottdiener</surname><given-names>J</given-names></name><name><surname>Seeman</surname><given-names>T</given-names></name><name><surname>Tracy</surname><given-names>R</given-names></name><name><surname>Kop</surname><given-names>WJ</given-names></name><name><surname>Burke</surname><given-names>G</given-names></name><name><surname>McBurnie</surname><given-names>MA</given-names></name><collab>Cardiovascular Health Study Collaborative Research G</collab></person-group><article-title>Frailty in older adults: evidence for a phenotype</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2001</year><volume>56</volume><fpage>M146</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">11253156</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwood</surname><given-names>K</given-names></name><name><surname>Mitnitski</surname><given-names>A</given-names></name></person-group><article-title>Frailty defined by deficit accumulation and geriatric medicine defined by frailty</article-title><source>Clin Geriatr Med</source><year>2011</year><volume>27</volume><fpage>17</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">21093719</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieliwonczyk</surname><given-names>E</given-names></name><name><surname>Perkisas</surname><given-names>S</given-names></name><name><surname>Vandewoude</surname><given-names>M</given-names></name></person-group><article-title>Frailty indexes, screening instruments and their application in Belgian primary care</article-title><source>Acta Clin Belg</source><year>2014</year><volume>69</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">24773077</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laksmi</surname><given-names>PW</given-names></name></person-group><article-title>Frailty syndrome: an emerging geriatric syndrome calling for its potential intervention</article-title><source>Acta Med Indones</source><year>2014</year><volume>46</volume><fpage>173</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">25348178</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clegg</surname><given-names>A</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Iliffe</surname><given-names>S</given-names></name><name><surname>Rikkert</surname><given-names>MO</given-names></name><name><surname>Rockwood</surname><given-names>K</given-names></name></person-group><article-title>Frailty in elderly people</article-title><source>Lancet</source><year>2013</year><volume>381</volume><fpage>752</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">23395245</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Mitnitski</surname><given-names>A</given-names></name><name><surname>Rockwood</surname><given-names>K</given-names></name></person-group><article-title>Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation</article-title><source>J Am Geriatr Soc</source><year>2010</year><volume>58</volume><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">20345864</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwood</surname><given-names>K</given-names></name><name><surname>Hogan</surname><given-names>DB</given-names></name><name><surname>MacKnight</surname><given-names>C</given-names></name></person-group><article-title>Conceptualisation and measurement of frailty in elderly people</article-title><source>Drugs Aging</source><year>2000</year><volume>17</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">11087007</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez-Otin</surname><given-names>C</given-names></name><name><surname>Blasco</surname><given-names>MA</given-names></name><name><surname>Partridge</surname><given-names>L</given-names></name><name><surname>Serrano</surname><given-names>M</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>The hallmarks of aging</article-title><source>Cell</source><year>2013</year><volume>153</volume><fpage>1194</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">23746838</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedarko</surname><given-names>NS</given-names></name></person-group><article-title>The biology of aging and frailty</article-title><source>Clin Geriatr Med</source><year>2011</year><volume>27</volume><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">21093720</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>KA</given-names></name><name><surname>Vallejo</surname><given-names>AN</given-names></name><name><surname>Studenski</surname><given-names>SA</given-names></name></person-group><article-title>Successful aging as a continuum of functional independence: lessons from physical disability models of aging</article-title><source>Aging Dis</source><year>2012</year><volume>3</volume><fpage>5</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">22500268</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ershler</surname><given-names>WB</given-names></name><name><surname>Keller</surname><given-names>ET</given-names></name></person-group><article-title>Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty</article-title><source>Annu Rev Med</source><year>2000</year><volume>51</volume><fpage>245</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">10774463</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>S</given-names></name><name><surname>Chaves</surname><given-names>P</given-names></name><name><surname>Koenig</surname><given-names>K</given-names></name><name><surname>Walston</surname><given-names>J</given-names></name></person-group><article-title>Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study</article-title><source>J Am Geriatr Soc</source><year>2002</year><volume>50</volume><fpage>1268</fpage><lpage>1271</lpage><pub-id pub-id-type="pmid">12133023</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>SX</given-names></name><name><surname>Cappola</surname><given-names>AR</given-names></name><name><surname>Andersen</surname><given-names>RE</given-names></name><name><surname>Blackman</surname><given-names>MR</given-names></name><name><surname>Koenig</surname><given-names>K</given-names></name><name><surname>Blair</surname><given-names>M</given-names></name><name><surname>Walston</surname><given-names>JD</given-names></name></person-group><article-title>Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty</article-title><source>Aging Clin Exp Res</source><year>2004</year><volume>16</volume><fpage>153</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">15195991</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>SX</given-names></name><name><surname>Xue</surname><given-names>QL</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Walston</surname><given-names>JD</given-names></name><name><surname>Fried</surname><given-names>LP</given-names></name></person-group><article-title>Inflammation and frailty in older women</article-title><source>J Am Geriatr Soc</source><year>2007</year><volume>55</volume><fpage>864</fpage><lpage>871</lpage><pub-id pub-id-type="pmid">17537086</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walston</surname><given-names>J</given-names></name><name><surname>Hadley</surname><given-names>EC</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Studenski</surname><given-names>SA</given-names></name><name><surname>Ershler</surname><given-names>WB</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name><name><surname>Fried</surname><given-names>LP</given-names></name></person-group><article-title>Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults</article-title><source>J Am Geriatr Soc</source><year>2006</year><volume>54</volume><fpage>991</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">16776798</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>LL</given-names></name><name><surname>Boter</surname><given-names>H</given-names></name><name><surname>Buskens</surname><given-names>E</given-names></name><name><surname>Slaets</surname><given-names>JP</given-names></name></person-group><article-title>Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people</article-title><source>J Am Med Dir Assoc</source><year>2012</year><volume>13</volume><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">22579590</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gobbens</surname><given-names>RJ</given-names></name><name><surname>van Assen</surname><given-names>MA</given-names></name><name><surname>Luijkx</surname><given-names>KG</given-names></name><name><surname>Wijnen-Sponselee</surname><given-names>MT</given-names></name><name><surname>Schols</surname><given-names>JM</given-names></name></person-group><article-title>The Tilburg Frailty Indicator: psychometric properties</article-title><source>J Am Med Dir Assoc</source><year>2010</year><volume>11</volume><fpage>344</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">20511102</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwood</surname><given-names>K</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>MacKnight</surname><given-names>C</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Hogan</surname><given-names>DB</given-names></name><name><surname>McDowell</surname><given-names>I</given-names></name><name><surname>Mitnitski</surname><given-names>A</given-names></name></person-group><article-title>A global clinical measure of fitness and frailty in elderly people</article-title><source>CMAJ</source><year>2005</year><volume>173</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">16129869</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garrett</surname><given-names>DD</given-names></name><name><surname>Tuokko</surname><given-names>H</given-names></name><name><surname>Stajduhar</surname><given-names>KI</given-names></name><name><surname>Lindsay</surname><given-names>J</given-names></name><name><surname>Buehler</surname><given-names>S</given-names></name></person-group><article-title>Planning for end-of-life care: findings from the Canadian Study of Health and Aging</article-title><source>Can J Aging</source><year>2008</year><volume>27</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">18492633</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Tsou</surname><given-names>HH</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name></person-group><article-title>Validation of the Chinese-Canadian study of health and aging clinical frailty scale (CSHA-CFS) telephone version</article-title><source>Arch Gerontol Geriatr</source><year>2010</year><volume>50</volume><fpage>e74</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">19608288</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conroy</surname><given-names>S</given-names></name><name><surname>Dowsing</surname><given-names>T</given-names></name></person-group><article-title>The ability of frailty to predict outcomes in older people attending an acute medical unit</article-title><source>Acute Med</source><year>2013</year><volume>12</volume><fpage>74</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">23732130</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martocchia</surname><given-names>A</given-names></name><name><surname>Frugoni</surname><given-names>P</given-names></name><name><surname>Indiano</surname><given-names>I</given-names></name><name><surname>Tafaro</surname><given-names>L</given-names></name><name><surname>Comite</surname><given-names>F</given-names></name><name><surname>Amici</surname><given-names>A</given-names></name><name><surname>Cacciafesta</surname><given-names>M</given-names></name><name><surname>Marigliano</surname><given-names>V</given-names></name><name><surname>Falaschi</surname><given-names>P</given-names></name></person-group><article-title>Screening of frailty in elderly patients with disability by the means of Marigliano-Cacciafesta polypathology scale (MCPS) and Canadian Study of Health and Aging (CSHA) scales</article-title><source>Arch Gerontol Geriatr</source><year>2013</year><volume>56</volume><fpage>339</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">23246500</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matusik</surname><given-names>P</given-names></name><name><surname>Tomaszewski</surname><given-names>K</given-names></name><name><surname>Chmielowska</surname><given-names>K</given-names></name><name><surname>Nowak</surname><given-names>J</given-names></name><name><surname>Nowak</surname><given-names>W</given-names></name><name><surname>Parnicka</surname><given-names>A</given-names></name><name><surname>Dubiel</surname><given-names>M</given-names></name><name><surname>Gasowski</surname><given-names>J</given-names></name><name><surname>Grodzicki</surname><given-names>T</given-names></name></person-group><article-title>Severe frailty and cognitive impairment are related to higher mortality in 12-month follow-up of nursing home residents</article-title><source>Arch Gerontol Geriatr</source><year>2012</year><volume>55</volume><fpage>22</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">21764151</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Groessl</surname><given-names>EJ</given-names></name><name><surname>Kaplan</surname><given-names>RM</given-names></name><name><surname>Rejeski</surname><given-names>WJ</given-names></name><name><surname>Katula</surname><given-names>JA</given-names></name><name><surname>King</surname><given-names>AC</given-names></name><name><surname>Frierson</surname><given-names>G</given-names></name><name><surname>Glynn</surname><given-names>NW</given-names></name><name><surname>Hsu</surname><given-names>FC</given-names></name><name><surname>Walkup</surname><given-names>M</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name></person-group><article-title>Health-related quality of life in older adults at risk for disability</article-title><source>Am J Prev Med</source><year>2007</year><volume>33</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">17826582</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>TR</given-names></name><name><surname>Bradley</surname><given-names>EH</given-names></name><name><surname>Williams</surname><given-names>CS</given-names></name><name><surname>Tinetti</surname><given-names>ME</given-names></name></person-group><article-title>Functional disability and health care expenditures for older persons</article-title><source>Arch Intern Med</source><year>2001</year><volume>161</volume><fpage>2602</fpage><lpage>2607</lpage><pub-id pub-id-type="pmid">11718592</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>TM</given-names></name><name><surname>Gahbauer</surname><given-names>EA</given-names></name><name><surname>Allore</surname><given-names>HG</given-names></name><name><surname>Han</surname><given-names>L</given-names></name></person-group><article-title>Transitions between frailty states among community-living older persons</article-title><source>Arch Intern Med</source><year>2006</year><volume>166</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">16505261</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name><name><surname>Studenski</surname><given-names>S</given-names></name><name><surname>Fried</surname><given-names>LP</given-names></name><name><surname>Cutler</surname><given-names>GB</given-names><suffix>Jr</suffix></name><name><surname>Walston</surname><given-names>JD</given-names></name><collab>Interventions on Frailty Working G</collab></person-group><article-title>Designing randomized, controlled trials aimed at preventing or delaying functional decline and disability in frail, older persons: a consensus report</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">15066083</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleman-Mateo</surname><given-names>H</given-names></name><name><surname>Macias</surname><given-names>L</given-names></name><name><surname>Esparza-Romero</surname><given-names>J</given-names></name><name><surname>Astiazaran-Garcia</surname><given-names>H</given-names></name><name><surname>Blancas</surname><given-names>AL</given-names></name></person-group><article-title>Physiological effects beyond the significant gain in muscle mass in sarcopenic elderly men: evidence from a randomized clinical trial using a protein-rich food</article-title><source>Clin Interv Aging</source><year>2012</year><volume>7</volume><fpage>225</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">22866000</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesari</surname><given-names>M</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Hsu</surname><given-names>FC</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Doss</surname><given-names>H</given-names></name><name><surname>King</surname><given-names>AC</given-names></name><name><surname>Manini</surname><given-names>TM</given-names></name><name><surname>Church</surname><given-names>T</given-names></name><name><surname>Gill</surname><given-names>TM</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name><name><surname>Group</surname><given-names>LS</given-names></name></person-group><article-title>A Physical Activity Intervention to Treat the Frailty Syndrome in Older Persons-Results From the LIFE-P Study</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2015</year><volume>70</volume><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">25387728</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fairhall</surname><given-names>N</given-names></name><name><surname>Sherrington</surname><given-names>C</given-names></name><name><surname>Kurrle</surname><given-names>SE</given-names></name><name><surname>Lord</surname><given-names>SR</given-names></name><name><surname>Lockwood</surname><given-names>K</given-names></name><name><surname>Howard</surname><given-names>K</given-names></name><name><surname>Hayes</surname><given-names>A</given-names></name><name><surname>Monaghan</surname><given-names>N</given-names></name><name><surname>Langron</surname><given-names>C</given-names></name><name><surname>Aggar</surname><given-names>C</given-names></name><name><surname>Cameron</surname><given-names>ID</given-names></name></person-group><article-title>Economic evaluation of a multifactorial, interdisciplinary intervention versus usual care to reduce frailty in frail older people</article-title><source>J Am Med Dir Assoc</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">25239014</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drey</surname><given-names>M</given-names></name><name><surname>Zech</surname><given-names>A</given-names></name><name><surname>Freiberger</surname><given-names>E</given-names></name><name><surname>Bertsch</surname><given-names>T</given-names></name><name><surname>Uter</surname><given-names>W</given-names></name><name><surname>Sieber</surname><given-names>CC</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name><name><surname>Bauer</surname><given-names>JM</given-names></name></person-group><article-title>Effects of strength training versus power training on physical performance in prefrail community-dwelling older adults</article-title><source>Gerontology</source><year>2012</year><volume>58</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">22056537</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faes</surname><given-names>MC</given-names></name><name><surname>Reelick</surname><given-names>MF</given-names></name><name><surname>Melis</surname><given-names>RJ</given-names></name><name><surname>Borm</surname><given-names>GF</given-names></name><name><surname>Esselink</surname><given-names>RA</given-names></name><name><surname>Rikkert</surname><given-names>MG</given-names></name></person-group><article-title>Multifactorial fall prevention for pairs of frail community-dwelling older fallers and their informal caregivers: a dead end for complex interventions in the frailest fallers</article-title><source>J Am Med Dir Assoc</source><year>2011</year><volume>12</volume><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">21450224</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>MJ</given-names></name><name><surname>Sloane</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>HJ</given-names></name><name><surname>Crowley</surname><given-names>GM</given-names></name><name><surname>Pieper</surname><given-names>CF</given-names></name><name><surname>Morey</surname><given-names>MC</given-names></name></person-group><article-title>Effect of telephone exercise counseling on frailty in older veterans: project LIFE</article-title><source>Am J Mens Health</source><year>2007</year><volume>1</volume><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">19482814</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solerte</surname><given-names>SB</given-names></name><name><surname>Gazzaruso</surname><given-names>C</given-names></name><name><surname>Bonacasa</surname><given-names>R</given-names></name><name><surname>Rondanelli</surname><given-names>M</given-names></name><name><surname>Zamboni</surname><given-names>M</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><name><surname>Locatelli</surname><given-names>E</given-names></name><name><surname>Schifino</surname><given-names>N</given-names></name><name><surname>Giustina</surname><given-names>A</given-names></name><name><surname>Fioravanti</surname><given-names>M</given-names></name></person-group><article-title>Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia</article-title><source>Am J Cardiol</source><year>2008</year><volume>101</volume><fpage>69E</fpage><lpage>77E</lpage><pub-id pub-id-type="pmid">18157968</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tieland</surname><given-names>M</given-names></name><name><surname>Dirks</surname><given-names>ML</given-names></name><name><surname>van der Zwaluw</surname><given-names>N</given-names></name><name><surname>Verdijk</surname><given-names>LB</given-names></name><name><surname>van de Rest</surname><given-names>O</given-names></name><name><surname>de Groot</surname><given-names>LC</given-names></name><name><surname>van Loon</surname><given-names>LJ</given-names></name></person-group><article-title>Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial</article-title><source>J Am Med Dir Assoc</source><year>2012</year><volume>13</volume><fpage>713</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">22770932</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>van den Beld</surname><given-names>AW</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Lamberts</surname><given-names>SW</given-names></name></person-group><article-title>Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>3988</fpage><lpage>3991</lpage><pub-id pub-id-type="pmid">16804050</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CM</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>WD</given-names></name><name><surname>Wu</surname><given-names>SC</given-names></name></person-group><article-title>The effectiveness of a comprehensive geriatric assessment intervention program for frailty in community-dwelling older people: a randomized, controlled trial</article-title><source>Arch Gerontol Geriatr</source><year>2010</year><volume>50</volume><issue>Suppl 1</issue><fpage>S39</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">20171455</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanina</surname><given-names>C</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name></person-group><article-title>Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?</article-title><source>Circ Res</source><year>2015</year><volume>117</volume><fpage>229</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">26185208</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karantalis</surname><given-names>V</given-names></name><name><surname>Schulman</surname><given-names>IH</given-names></name><name><surname>Balkan</surname><given-names>W</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name></person-group><article-title>Allogeneic cell therapy: a new paradigm in therapeutics</article-title><source>Circ Res</source><year>2015</year><volume>116</volume><fpage>12</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">25552688</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>A</given-names></name><name><surname>Ichim</surname><given-names>TE</given-names></name><name><surname>Marleau</surname><given-names>AM</given-names></name><name><surname>Lara</surname><given-names>F</given-names></name><name><surname>Kaushal</surname><given-names>S</given-names></name><name><surname>Riordan</surname><given-names>NH</given-names></name></person-group><article-title>Immune effects of mesenchymal stem cells: implications for Charcot-Marie-Tooth disease</article-title><source>Cell Immunol</source><year>2008</year><volume>253</volume><fpage>11</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">18627903</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>RH</given-names></name><name><surname>Seo</surname><given-names>MJ</given-names></name><name><surname>Reger</surname><given-names>RL</given-names></name><name><surname>Spees</surname><given-names>JL</given-names></name><name><surname>Pulin</surname><given-names>AA</given-names></name><name><surname>Olson</surname><given-names>SD</given-names></name><name><surname>Prockop</surname><given-names>DJ</given-names></name></person-group><article-title>Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>17438</fpage><lpage>17443</lpage><pub-id pub-id-type="pmid">17088535</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>K</given-names></name><name><surname>Leelahavanichkul</surname><given-names>A</given-names></name><name><surname>Yuen</surname><given-names>PS</given-names></name><name><surname>Mayer</surname><given-names>B</given-names></name><name><surname>Parmelee</surname><given-names>A</given-names></name><name><surname>Doi</surname><given-names>K</given-names></name><name><surname>Robey</surname><given-names>PG</given-names></name><name><surname>Leelahavanichkul</surname><given-names>K</given-names></name><name><surname>Koller</surname><given-names>BH</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Jelinek</surname><given-names>I</given-names></name><name><surname>Star</surname><given-names>RA</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name></person-group><article-title>Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">19098906</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parekkadan</surname><given-names>B</given-names></name><name><surname>van Poll</surname><given-names>D</given-names></name><name><surname>Suganuma</surname><given-names>K</given-names></name><name><surname>Carter</surname><given-names>EA</given-names></name><name><surname>Berthiaume</surname><given-names>F</given-names></name><name><surname>Tilles</surname><given-names>AW</given-names></name><name><surname>Yarmush</surname><given-names>ML</given-names></name></person-group><article-title>Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure</article-title><source>PLoS One</source><year>2007</year><volume>2</volume><fpage>e941</fpage><pub-id pub-id-type="pmid">17895982</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raggi</surname><given-names>C</given-names></name><name><surname>Berardi</surname><given-names>AC</given-names></name></person-group><article-title>Mesenchymal stem cells, aging and regenerative medicine</article-title><source>Muscles Ligaments Tendons J</source><year>2012</year><volume>2</volume><fpage>239</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">23738303</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>VK</given-names></name><name><surname>Lucas</surname><given-names>KG</given-names></name><name><surname>Kleiner</surname><given-names>GI</given-names></name><name><surname>Talano</surname><given-names>JA</given-names></name><name><surname>Jacobsohn</surname><given-names>D</given-names></name><name><surname>Broadwater</surname><given-names>G</given-names></name><name><surname>Monroy</surname><given-names>R</given-names></name><name><surname>Kurtzberg</surname><given-names>J</given-names></name></person-group><article-title>Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study</article-title><source>Biol Blood Marrow Transplant</source><year>2011</year><volume>17</volume><fpage>534</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">20457269</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>AN</given-names></name><name><surname>Genovese</surname><given-names>J</given-names></name></person-group><article-title>Potential clinical applications of adult human mesenchymal stem cell (Prochymal(R)) therapy</article-title><source>Stem Cells Cloning</source><year>2011</year><volume>4</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">24198531</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Premer</surname><given-names>C</given-names></name><name><surname>Blum</surname><given-names>A</given-names></name><name><surname>Bellio</surname><given-names>MA</given-names></name><name><surname>Schulman</surname><given-names>IH</given-names></name><name><surname>Hurwitz</surname><given-names>BE</given-names></name><name><surname>Parker</surname><given-names>M</given-names></name><name><surname>Dermarkarian</surname><given-names>CR</given-names></name><name><surname>DiFede</surname><given-names>DL</given-names></name><name><surname>Balkan</surname><given-names>W</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name></person-group><article-title>Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells</article-title><source>EBioMedicine</source><year>2015</year><volume>2</volume><fpage>467</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">26137590</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Bolli</surname><given-names>R</given-names></name><name><surname>Cooke</surname><given-names>JP</given-names></name><name><surname>Gordon</surname><given-names>DJ</given-names></name><name><surname>Henry</surname><given-names>TD</given-names></name><name><surname>Perin</surname><given-names>EC</given-names></name><name><surname>March</surname><given-names>KL</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Pepine</surname><given-names>CJ</given-names></name><name><surname>Simari</surname><given-names>RD</given-names></name><name><surname>Skarlatos</surname><given-names>SI</given-names></name><name><surname>Traverse</surname><given-names>JH</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name><name><surname>Szady</surname><given-names>AD</given-names></name><name><surname>Taylor</surname><given-names>DA</given-names></name><name><surname>Vojvodic</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN)</article-title><source>Circulation</source><year>2013</year><volume>127</volume><fpage>1630</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">23588961</pub-id></element-citation></ref></ref-list></back></article>